Abstract
Protease inhibitors (PIs) inhibit the cytochrome P450 CYP3A4 [1]. Because the metabolism of pravastatin is independent of the cytochrome P450 CYP3A4, this drug has become the preferred statin for treatment of dyslipidemia associated with human immunodeficiency virus (HIV) infection, with no cases of serious toxicity such as rhabdomyolysis reported to date. We report an HIV-infected patient receiving antiretroviral regimen consisting of atazanavir, ritonavir, emtricitabine and tenofovir who developed severe rhabdomyolysis approximately 4 months after increasing his pravastatin dose from 40 to 80 mg daily. His symptoms resolved within 10 days after the discontinuation of pravastatin and antiretroviral therapy. To our knowledge, this is the first case of rhabdomyolysis possibly caused by pravastatin in an HIV-infected patient.
Current Drug Safety
Title: Rhabdomyolysis in an HIV-Infected Patient on Anti-Retroviral Therapy Precipitated by High-Dose Pravastatin
Volume: 4 Issue: 2
Author(s): Nasser Mikhail, Elizabeth Iskander and Dennis Cope
Affiliation:
Abstract: Protease inhibitors (PIs) inhibit the cytochrome P450 CYP3A4 [1]. Because the metabolism of pravastatin is independent of the cytochrome P450 CYP3A4, this drug has become the preferred statin for treatment of dyslipidemia associated with human immunodeficiency virus (HIV) infection, with no cases of serious toxicity such as rhabdomyolysis reported to date. We report an HIV-infected patient receiving antiretroviral regimen consisting of atazanavir, ritonavir, emtricitabine and tenofovir who developed severe rhabdomyolysis approximately 4 months after increasing his pravastatin dose from 40 to 80 mg daily. His symptoms resolved within 10 days after the discontinuation of pravastatin and antiretroviral therapy. To our knowledge, this is the first case of rhabdomyolysis possibly caused by pravastatin in an HIV-infected patient.
Export Options
About this article
Cite this article as:
Mikhail Nasser, Iskander Elizabeth and Cope Dennis, Rhabdomyolysis in an HIV-Infected Patient on Anti-Retroviral Therapy Precipitated by High-Dose Pravastatin, Current Drug Safety 2009; 4 (2) . https://dx.doi.org/10.2174/157488609788173080
DOI https://dx.doi.org/10.2174/157488609788173080 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Ultrafiltration-based Extraction and LC-MS/MS Quantification of Phenylalanine in Human Blood Sample for Metabolite Target Analysis
Current Pharmaceutical Analysis Meet Our Editorial Board Member
Reviews on Recent Clinical Trials The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review
Current Neuropharmacology Prolylcarboxypeptidase Gene Expression in the Heart and Kidney: Effects of Obesity and Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Potential of Antibiotics for the Treatment and Management of Parkinson's Disease: An Overview
Current Drug Research Reviews A Possible New Diagnostic Biomarker in Early Diagnosis of Alzheimers Disease
Current Alzheimer Research Endothelial Dysfunction in Renal Failure: Current Update
Current Medicinal Chemistry Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?
Current Pharmaceutical Design Oxidative Stress Upregulates PDCD4 Expression in Patients with Gastric Cancer via miR-21
Current Pharmaceutical Design Snake Venom: From Deadly Toxins to Life-saving Therapeutics
Current Medicinal Chemistry Targeting Neurotrophin Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Fetal Mechanisms That Lead to Later Hypertension
Current Drug Targets Can We Delay the Accelerated Lung Aging in COPD? Anti-Aging Molecules and Interventions
Current Drug Targets Xanthine Oxidase Perspective in Human Health
Current Biotechnology Gene Polymorphism of Angiotensin II Type 1 and Type 2 Receptors
Current Pharmaceutical Design The Complications of Bariatric Surgery Patients with Type 2 Diabetes in the World: A Systematic Review and Meta-Analysis
Current Diabetes Reviews The effect of Endovascular Aneurysm Repair on Renal Function in Patients Treated for Abdominal Aortic Aneurysm
Current Pharmaceutical Design Podocyte Mitosis – A Catastrophe
Current Molecular Medicine Nanomedicine in the Diagnosis and Treatment of Atherosclerosis-A Systematic Review
Cardiovascular & Hematological Disorders-Drug Targets